Zürcher Nachrichten - Formerra and Evonik Expand Distribution Partnership for Healthcare Grades

EUR -
AED 4.137978
AFN 73.238598
ALL 92.247061
AMD 408.408321
ANG 2.01729
AOA 1034.354674
ARS 1718.141089
AUD 1.619123
AWG 2.028146
AZN 1.92014
BAM 1.961122
BBD 2.268988
BDT 138.500941
BGN 1.896813
BHD 0.424637
BIF 3398.602328
BMD 1.126748
BND 1.441813
BOB 13.535251
BRL 5.9001
BSD 1.126572
BTN 109.137298
BWP 15.57371
BYN 3.393208
BYR 22084.255298
BZD 2.265648
CAD 1.604979
CDF 2602.787683
CHF 0.934254
CLF 0.028041
CLP 1107.232042
CNY 7.554394
CNH 7.554151
COP 3688.408659
CRC 516.200844
CUC 1.126748
CUP 27.036731
CVE 110.567999
CZK 24.436884
DJF 200.604392
DKK 7.474754
DOP 67.263432
DZD 150.576684
EGP 58.942201
ERN 16.901216
ETB 184.001937
FJD 2.532084
FKP 0.854001
GBP 0.851331
GEL 2.923898
GGP 0.854001
GHS 13.230434
GIP 0.854001
GMD 82.818885
GNF 9909.54029
GTQ 8.609057
GYD 235.649495
HKD 8.841956
HNL 30.245482
HRK 7.529383
HTG 147.520334
HUF 368.342854
IDR 20169.516562
ILS 3.439206
IMP 0.854001
INR 108.278034
IQD 1475.824676
IRR 1967908.834771
ISK 137.203471
JEP 0.854001
JMD 178.343982
JOD 0.798844
JPY 177.76981
KES 146.1955
KGS 98.534379
KHR 4569.400241
KMF 493.515737
KPW 1014.073306
KRW 1516.501364
KWD 0.347895
KYD 0.938748
KZT 506.153578
LAK 25304.670723
LBP 100877.375478
LKR 372.537752
LRD 192.632758
LSL 18.835346
LTL 3.326993
LVL 0.681559
LYD 7.214579
MAD 11.192672
MDL 20.131632
MGA 4977.507746
MKD 61.748392
MMK 2366.033362
MNT 4054.45258
MOP 9.10561
MRU 45.015563
MUR 54.253041
MVR 17.40805
MWK 1953.401055
MXN 20.473338
MYR 4.602988
MZN 72.010646
NAD 18.836268
NGN 1497.323736
NIO 41.451016
NOK 10.838276
NPR 174.619676
NZD 2.006084
OMR 0.433216
PAB 1.126557
PEN 3.903755
PGK 5.101981
PHP 70.436345
PKR 312.010143
PLN 4.380062
PYG 6590.974044
QAR 4.106398
RON 5.350699
RSD 117.482569
RUB 94.366365
RWF 1668.427707
SAR 4.232543
SBD 9.087053
SCR 15.564581
SDG 677.727953
SEK 11.302497
SGD 1.440429
SHP 0.853467
SLE 27.706711
SLL 23627.327152
SOS 643.824327
SRD 42.60402
STD 23321.402895
STN 24.566996
SVC 9.85688
SYP 14649.974133
SZL 18.831435
THB 37.810263
TJS 10.369741
TMT 3.954884
TND 3.356955
TOP 2.712938
TRY 55.373566
TTD 7.63873
TWD 35.858188
TZS 2968.98363
UAH 50.691013
UGX 4495.258883
USD 1.126748
UYU 45.404425
UZS 13287.412588
VES 975.175324
VND 29279.10286
VUV 135.30472
WST 3.13334
XAF 655.957
XAG 0.018668
XAU 0.00027177463
XCD 3.045092
XCG 2.03031
XDR 0.796669
XOF 655.957
XPF 119.331742
YER 266.335012
ZAR 18.758343
ZMK 10142.062004
ZMW 22.136072
ZWL 362.812306
SSP 6436.649895
MXV 2.316522
  • CMSC

    0.3300

    20.49

    +1.61%

  • JRI

    0.1000

    10.87

    +0.92%

  • AZN

    -1.0500

    156.65

    -0.67%

  • GSK

    -0.1850

    46.995

    -0.39%

  • RIO

    0.6900

    93.56

    +0.74%

  • NGG

    0.6400

    75.97

    +0.84%

  • BTI

    0.0899

    52.445

    +0.17%

  • BCC

    0.3500

    75.05

    +0.47%

  • BCE

    0.1150

    20.035

    +0.57%

  • RYCEF

    0.3000

    19.7

    +1.52%

  • RBGPF

    0.0000

    65

    0%

  • CMSD

    0.2650

    20.605

    +1.29%

  • BP

    0.2400

    44.74

    +0.54%

  • RELX

    -0.0650

    33.425

    -0.19%

  • VOD

    0.4100

    16.79

    +2.44%

Formerra and Evonik Expand Distribution Partnership for Healthcare Grades
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades

Formerra and Evonik Expand Distribution Partnership for Healthcare Grades

Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada

Text size:

ROMEOVILLE, ILLINOIS / ACCESS Newswire / February 2, 2026 / Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications.

This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup.

With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgical instrument parts, medical device housings, components that see short-term body contact (

Key medical grade materials include:

  • VESTAMID® Care ML PA12

  • VESTAMID® Care ME PEBA elastomer

  • TROGAMID® Care MX microcrystalline PA

"Our healthcare customers rely on stable supply, world-class regulatory support, and materials that perform under demanding conditions," said Steve Harmon, Director, Key Accounts, Formerra. "Evonik's healthcare grades bring the combination of durability, processing consistency, and documentation support that medical manufacturers require. This expansion lets us strengthen the technical resources and materials pipeline available to teams developing next-generation devices."

"Formerra's ability to serve the whole supply chain in the medical space, from design companies to compounders to medical device OEMs, with technical rigor and exceptional logistics and with already-proven successful demonstration in the industrial space, made this expansion with CARE brand Polyamide 12 products a natural step," said Basker Lalgudi, Business Manager, Global Medical Devices, Evonik. "Their healthcare expertise and focus help customers select and implement our materials with confidence across a range of critical applications."

By adding Evonik's healthcare CARE brand materials, Formerra will offer customers a proven set of polyamide solutions that support regulatory pathways, design requirements, and long-term reliability. Formerra's team will provide material selection guidance, processing support, and regional supply chain readiness to help OEMs and molders accelerate development cycles.

Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, Feb. 3-5, 2026.

Key Details:

  • Formerra will distribute Evonik's CARE brand healthcare grades across the U.S. and Canada.

  • Materials include healthcare grades within the VESTAMID® L, VESTAMID® E, and TROGAMID® CX families, plus designated sustainable options.

  • The agreement strengthens Formerra's medical portfolio and expands its support for fluid management, diagnostics, wearables, and device housings.

  • Formerra will provide application guidance, regulatory documentation support, and supply chain continuity for medical customers.

About Formerra

Formerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways, driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.

About Evonik

Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day. To learn more, visit www.evonik.com.

Media Contact
Jackie Morris
Marketing Communications Manager, Formerra
[email protected]
+1 630-972-3144

SOURCE: Formerra



View the original press release on ACCESS Newswire

P.E.Steiner--NZN